Featured Publications
Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer
Lavi E, Lin Z, Ratner E. Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer. IScience 2023, 26: 107934. PMID: 37810216, PMCID: PMC10558711, DOI: 10.1016/j.isci.2023.107934.Peer-Reviewed Original ResearchOvarian cancer patientsClinical outcomesCancer patientsDisease progressionOvarian cancerFive-year overall survival rateOverall survival rateDeadliest gynecologic malignancyLogistic regression modelsGynecologic malignanciesPatient survivalPrognostic biomarkerSurvival rateSample t-testPatientsT-testCancerProgressionRegression modelsOutcomesExpression profilesGene expressionMalignancyPrognosisRecurrence
2023
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Roberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers 2023, 15: 3919. PMID: 37568736, PMCID: PMC10417836, DOI: 10.3390/cancers15153919.Peer-Reviewed Original ResearchEpithelial ovarian cancerRepair gene expressionPARP inhibitorsHomologous recombinationGene expressionDNA repair gene expressionCancer cellsLethal gynecologic malignancyDrug-resistant recurrenceDownregulation of genesOvarian cancer cellsGrowth factor betaWild-type cancer cellsDose-dependent mannerDNA repair genesGynecologic malignanciesMesenchymal tumorsOvarian tumorsEpithelial cell lineOvarian cancerMetastatic spreadClinical utilityEOC cellsFunctions of EMTFactor beta